Active, Not Recruiting

Trial purpose

The goal of this study is to evaluate the efficacy and safety of pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib as first-line treatment in participants with advanced clear cell renal cell carcinoma (ccRCC).

The primary hypotheses are (1) pembrolizumab plus belzutifan plus lenvatinib is superior to pembrolizumab plus lenvatinib with respect to progression-free survival (PFS) and overall survival (OS), in advanced ccRCC participants; and (2) pembrolizumab/quavonlimab plus lenvatinib is superior to pembrolizumab plus lenvatinib with respect to PFS and OS, in advanced ccRCC participants.

View full trial information on Clinicaltrials.gov
NATIONAL TRIAL REFERENCE NUMBER NCT04736706
Conditions Carcinoma, Renal Cell
Age Range 18+
Sex All
Current trial phase 1
Trial start and end dates [04-14-2021] [10-29-2026]

About the trial

Eligibility

Only a qualified healthcare professional can determine if you are eligible to take part in a clinical trial. However, this information may be useful in starting a conversation with your doctor.

Conditions

Carcinoma, Renal Cell

View full trial eligibility

All patients who enroll in the trial will receive medication while on the study.

33% will receive pembrolizumab plus MK-6482 and lenvatinib

33% will receive MK-1308A (pembrolizumab with MK-1308) plus lenvatinib

33% will receive pembrolizumab plus lenvatinib

*A computer will decide which group you are put in. You have a 1 in 3 chance of getting put in each group. You, your trial doctor, and the trial staff will know what you are getting.

Phase 3

In Phase 3 trials, researchers try to find out if a treatment works in a large number of people, usually about 1,000 to 5,000 participants who have the health condition the treatment is intended to treat. In vaccine trials, the participants may be healthy or have diseases or conditions. Phase 3 trials may happen in a doctor’s office, a clinic, or a hospital.

Trial locations (0)

Locations shown may have changed in some cases. Please call the number listed in the location results to confirm the nearest trial site. Talk with a trial site member for more information.

What can you do next?

Discuss with your doctor or care team

Print this page with details about the trial or email it to your doctor to discuss the clinical trial during your next visit.

Get help talking with your doctor or care team

NATIONAL TRIAL REFERENCE NUMBER

NCT04736706

When you talk with your doctor or clinical trial team member, please have the national trial reference number available.

This site is registered on wpml.org as a development site. Switch to a production site key to remove this banner.